Genvor to Showcase Next-Generation Plant Health Solutions at Leading Industry Event

CHAPEL HILL, NC / ACCESSWIRE / February 20, 2024 / Genvor Incorporated (OTCQB:GNVR) ("Genvor" or the "Company"), a developer of sustainable plant health solutions leveraging patented peptides, today announced that management will attend the BioSolutions Conference & Expo taking place March 4-6, 2024 in Visalia, California.

Now in its 9th year, the BioSolutions Conference & Expo is a production-focused event offering North American growers, advisers, and researchers the latest information and real-world guidance on implementing biological solutions and technology tools in specialty crop production.

Chad Pawlak, Chief Executive Officer of Genvor, plans to participate in one-on-one meetings with industry participants, investors and the media throughout the conference.

BioSolutions Conference & Expo

Date: March 4-6, 2024

Location: Visalia Marriott and Convention Center | Visalia, California

Event Website: https://www.biosolutionsconference.com

Pawlak commented: "Biologicals, such as the peptide-based plant health solutions we are pioneering at Genvor today, are positioned to revolutionize the future of agriculture. To that end, the BioSolutions Conference & Expo represents an excellent venue to share Genvor's story with key industry participants - including strategics, the trade media, regulators and investors. I look forward to a productive day of meetings at the event as we strive to create sustainable, long-term value for our shareholders."

For more information or to register for the event, please visit the conference website. To schedule a one-on-one meeting at the conference, please email your request to GNVR@mzgroup.us or call Lucas A. Zimmerman at (949) 259-4987.

About Genvor

Genvor Incorporated (OTCQB:GNVR) is a developer of sustainable plant health solutions, with a portfolio of patented peptides to provide crops with anti-pathogen and enhanced nutritional properties through next-generation biological foliar application as well as transgenic seed traits. Supported by globally renowned scientists and a USDA partnership, Genvor leverages its licensing-first business model with active trait developments underway for a variety of crops including corn, citrus, rice, cotton, soybean, flax, and potato. To learn more, please visit www.genvor.com or follow us on LinkedIn, Facebook or Instagram.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements include information about management's view of the Company's future expectations, plans and prospects, including future business opportunities or strategies and are generally preceded by words such as "may," "believe," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "eventually" or "projected." You are cautioned that such statements are subject to a multitude of known and unknown risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. Certain of these risk factors and others are included in documents the Company files with the Securities and Exchange Commission, including but not limited to, the Company's Annual Report on Form 10-K, as well as subsequent reports filed with the Securities and Exchange Commission.

Investor Relations Contact:
Lucas A. Zimmerman
Managing Director
MZ Group - MZ North America
(949) 259-4987
GNVR@mzgroup.us
www.mzgroup.us

SOURCE: Genvor Incorporated